Cidara Therapeutics Inc (CDTX)
14.66
+0.72
(+5.16%)
USD |
NASDAQ |
Nov 14, 16:00
14.66
0.00 (0.00%)
After-Hours: 18:04
Cidara Therapeutics Free Cash Flow: -125.11M for June 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2024 | -125.11M |
| March 31, 2024 | -18.61M |
| December 31, 2023 | -22.94M |
| September 30, 2023 | -31.05M |
| June 30, 2023 | -1.324M |
| March 31, 2023 | -15.89M |
| December 31, 2022 | -28.59M |
| September 30, 2022 | -22.49M |
| June 30, 2022 | -62.44M |
| March 31, 2022 | -47.16M |
| December 31, 2021 | -25.27M |
| September 30, 2021 | -21.49M |
| June 30, 2021 | -23.65M |
| March 31, 2021 | -41.24M |
| December 31, 2020 | -54.60M |
| September 30, 2020 | -58.67M |
| June 30, 2020 | -27.91M |
| March 31, 2020 | -26.58M |
| December 31, 2019 | -28.57M |
| September 30, 2019 | -27.08M |
| Date | Value |
|---|---|
| June 30, 2019 | -56.56M |
| March 31, 2019 | -59.28M |
| December 31, 2018 | -56.88M |
| September 30, 2018 | -52.81M |
| June 30, 2018 | -53.80M |
| March 31, 2018 | -50.33M |
| December 31, 2017 | -50.22M |
| September 30, 2017 | -52.42M |
| June 30, 2017 | -46.32M |
| March 31, 2017 | -43.87M |
| December 31, 2016 | -40.17M |
| September 30, 2016 | -35.53M |
| June 30, 2016 | -35.63M |
| March 31, 2016 | -31.99M |
| December 31, 2015 | -27.13M |
| September 30, 2015 | -23.25M |
| June 30, 2015 | -18.78M |
| March 31, 2015 | -14.37M |
| December 31, 2014 | -8.701M |
Free Cash Flow Range, Past 5 Years
-125.11M
Minimum
Jun 2024
-1.324M
Maximum
Jun 2023
-35.98M
Average
-27.91M
Median
Jun 2020
Free Cash Flow Benchmarks
| Biomarin Pharmaceutical Inc | 300.88M |
| Arbutus Biopharma Corp | -71.92M |
| GlycoMimetics Inc | -35.72M |
| FibroGen Inc | -202.99M |
| Cue Biopharma Inc | -38.60M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -103.78M |
| Cash from Financing (Quarterly) | 239.13M |
| Free Cash Flow Per Share (Quarterly) | -22.74 |
| Free Cash Flow to Equity (Quarterly) | -103.78M |
| Free Cash Flow to Firm (Quarterly) | -103.78M |
| Free Cash Flow Yield | -188.1% |